— Know what they know.
Not Investment Advice

BLLN NASDAQ

BillionToOne, Inc.
1W: +10.3% 1M: -9.4% 3M: -16.6% YTD: +24.8%
$115.12
+3.65 (+3.28%)
 
Weekly Expected Move ±9.1%
$88 $98 $108 $118 $127
NASDAQ · Healthcare · Medical - Diagnostics & Research · Tech Score Buy · Power 60 · $5.3B mcap · 6M float · 12.08% daily turnover · Short 70% of daily vol
Credit Risk of going bust: higher than 55% of companies Debt: 2.7% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.36 (down 99.7%), BillionToOne, Inc. would be worth roughly what it owes.
Total debt $143.9M against a stock market value of $5.26B.
Distance to default 4.68 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $45.5M (short-term plus half of long-term), stock volatility 94.1%; Altman Z'' 7.52. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Smart Money Score
Moderate 50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$5.3B
52W Range61.96-150.44
Volume404,711
Avg Volume676,603
Beta0.34
Dividend—
Analyst Ratings
3 Buy 1 Hold 0 Sell
Consensus Buy
Company Info
CEOOguzhan Atay
Employees713
SectorHealthcare
IndustryMedical - Diagnostics & Research
IPO Date2025-11-06
1035 O’Brien Drive
Menlo Park, CA 94025
US
(650) 460-2551
About BillionToOne, Inc.

BillionToOne, Inc. is a specialized diagnostics company that innovates by precisely quantifying biological data to create advanced molecular diagnostic solutions. Central to their operations is a cutting-edge molecular counting platform, meticulously engineered to identify and measure individual DNA molecules, thereby significantly enhancing the precision of disease detection. Their product portfolio includes: UNITY Complete: A non-invasive prenatal screen that assesses a fetus's risk for aneuploidies, recessive genetic conditions, and fetal antigens, all from a simple maternal blood sample. Northstar Select: A liquid biopsy test designed to pinpoint specific mutations present in tumors, encompassing deletions, insertions, and point mutations. Northstar Response: A diagnostic tool that enables continuous tracking of cancer progression through detailed methylation assessment. Established in 2016, BillionToOne, Inc. conducts its operations from its headquarters located in Menlo Park, California.

Recent Insider Trades

NameTypeSharesPriceDate
Atay Oguzhan S-Sale 900 $98.43 2026-10-15
Atay Oguzhan S-Sale 1,861 $99.84 2026-10-15
Atay Oguzhan S-Sale 1,276 $100.60 2026-10-15
Atay Oguzhan S-Sale 980 $101.79 2026-10-15
Atay Oguzhan S-Sale 133 $102.78 2026-10-15

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms